fda compounding semaglutide warning november 2025 FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products

FDA is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified

26.51

★★★★☆4.8 (126)

WRTV Investigates has learned the FDA sent 30 warning letters to telehealth companies for illegally marketing compounded GLP-1s. MORE

25.14

★★★★★4.9 (98)

The FDA has announced that it has given us an expedited review of the once-a-day weight loss pill we're investigating, potentially giving people living with obesity a new treatment option early next

26.93

★★★★★5.0 (157)

The FDA has removed semaglutide injection products (GLP-1) from the shortage list, ending the temporary rule that allowed pharmacies to compound these medications, often used for weight loss. Compounded drugs are custom-made

23.69

★★★★★4.7 (84)

Safest and Cheapest Compounding Pharmacy for Semaglutide

21.65

★★★★★4.9 (203)

FDA Drug Recalls and Warnings: Illegal GLP-1 Sales and Misleading Marketing by Novo Nordisk and Eli Lilly

20.13

★★★★★5.0 (176)

The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide

24.63

★★★★★4.8 (132)